(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 6.9% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Abbvie's revenue in 2025 is $57,367,000,000.On average, 7 Wall Street analysts forecast ABBV's revenue for 2025 to be $106,338,654,547,443, with the lowest ABBV revenue forecast at $105,500,187,190,602, and the highest ABBV revenue forecast at $108,219,250,230,930. On average, 7 Wall Street analysts forecast ABBV's revenue for 2026 to be $115,300,662,814,006, with the lowest ABBV revenue forecast at $112,367,962,159,578, and the highest ABBV revenue forecast at $118,935,137,727,031.
In 2027, ABBV is forecast to generate $123,716,015,270,191 in revenue, with the lowest revenue forecast at $119,846,912,575,896 and the highest revenue forecast at $127,590,646,805,961.